Ribaxamase May Prevent Opportunistic Infections During IV β-lactam Treatment
Fecal sampling was done to evaluate changes in the microbiome of the gut and to detect colonization of opportunistic pathogens.
|This article is part of Infectious Disease Advisor's coverage of IDWeek 2017™, taking place in San Diego, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2017.|
Disclosures: All authors are employed by Synthetic Biologics, Inc.
|Visit Infectious Disease Advisor's conference section for continuous coverage live from IDWeek 2017.|